ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 031

Exome Sequencing for Early Pediatric Systemic Lupus Erythematosus: Standard of Care in 2020?

Yike Jiang1, Bo Yuan 1, Marietta DeGuzman 1, M. Cecilia Poli 2, Justin Branch 1, Andrea Ramirez 3, Martha Curry 1, Maria Pereira 4, Amanda Brown 1, W. Blaine Lapin 5, Sarah Nicholas 1, Lisa Forbes 1, Nicholas Rider 1, Levi Watkin 1, Jennifer Rammel 6, Ankur Kamdar 7, Melissa Mizesko 8, Juan Carlos Becerra 9, Emilina Lim 10, Eyal Muscal 11, Anaid Reyes 1, Zeynep Coban-Akdemir 1, James Lupski 1, Ivan Chinn 1 and Tiphanie Vogel 1, 1Baylor College of Medicine, Houston, 2Universidad del Desarrollo, Santiago, Chile, 3Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 4Assistant Professor, Section of Rheumatology, Division of Pediatrics, Baylor College of Medicine, Houston, Texas, 5, 6Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, 7Houston, 8Driscoll Children's Hospital, Corpus Christi, 9Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, 10Children's Hospital Orange County, Orange County, 11Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: genetics, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Title: Poster Breakout 5 – Systemic Lupus Erythematosus

Session Type: Poster Breakout Session

Session Time: 4:30PM-5:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with multifactorial etiology. Identification of monogenic causes of pediatric SLE (pSLE) has yielded important insights into pathogenesis and can illuminate therapeutic targets. Advances in genetics have made exome sequencing accessible and integral to clinical medicine in multiple disciplines. We used exome sequencing to determine genetic causes of pSLE, aiming to identify a clinically actionable target age for sequencing pSLE patients.

Methods: We identified 48 pSLE patients at 6 centers, 41 at Texas Children’s Hospital. Patients were included if they fulfilled classification criteria for SLE and had pre-pubertal disease onset. We performed research exome sequencing (45 patients), or research reanalysis of clinical sequencing (3 patients). Results are currently available for 31 patients.

Results: Our pSLE cohort is 77% female, 25% African American/Black, and 56% White; 52% of the patients are Hispanic. The age at SLE onset was an average of 8.4 years (range 1.75-14 years). Predominant clinical features include arthritis (75%), cutaneous disease (69%), and nephritis (56%, 41% of which was Class IV). Patients were largely leuko- or lymphopenic (73%) with hemolytic anemia (60%) and hypocomplementemia (88%). Progression to end-stage renal disease occurred in 4 patients (8%), 1 patient died of disease complications.

Exome sequencing was conducted on 30 trios (including both parents), 13 duos and 5 probands only. A monogenic etiology of disease was found in 4/31 available cases (13%): COPA syndrome, RAS-associated autoimmune leukoproliferative disorder, lysinuric protein intolerance and compound heterozygous variants in DNASE1L3. The average age of disease onset for solved patients was 3.4 years. Of the 5 patients with disease onset less than 5 years of age, 3 were found to have a monogenic etiology (60%). Patients with single variants in additional SLE-associated genes (RNASEH2, SAMHD1and PRKCD) are undergoing copy number variation (CNV) analysis. Variants in complement and complement regulatory proteins are enriched in our cohort and bioinformatic analysis of the significance of this finding is underway. A novel candidate gene has been identified and is under active investigation.

Conclusion: Onset of SLE in pre-pubertal patients is uncommon, and onset in early childhood is exceedingly rare. Access to genetic testing is increasing, coupled with a growing number of elucidated genes causing pSLE. Early identification of monogenic disease can direct alternative therapies. Further, there is an impact on family planning for families with an autosomal dominant genetic disorder, as uncovered in our cohort. Therefore, sequencing patients with pSLE with an age of onset below 5 years should be an essential part of clinical care.


Disclosure: Y. Jiang, None; B. Yuan, Baylor Genetics, 1; M. DeGuzman, None; M. Poli, None; J. Branch, None; A. Ramirez, None; M. Curry, None; M. Pereira, None; A. Brown, None; W. Lapin, None; S. Nicholas, None; L. Forbes, None; N. Rider, None; L. Watkin, None; J. Rammel, None; A. Kamdar, None; M. Mizesko, None; J. Becerra, None; E. Lim, None; E. Muscal, None; A. Reyes, None; Z. Coban-Akdemir, None; J. Lupski, Baylor Genetics, 1, 23andMe, 1, Regeneron Pharmaceuticals, 1, Other, 1; I. Chinn, None; T. Vogel, None.

To cite this abstract in AMA style:

Jiang Y, Yuan B, DeGuzman M, Poli M, Branch J, Ramirez A, Curry M, Pereira M, Brown A, Lapin W, Nicholas S, Forbes L, Rider N, Watkin L, Rammel J, Kamdar A, Mizesko M, Becerra J, Lim E, Muscal E, Reyes A, Coban-Akdemir Z, Lupski J, Chinn I, Vogel T. Exome Sequencing for Early Pediatric Systemic Lupus Erythematosus: Standard of Care in 2020? [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/exome-sequencing-for-early-pediatric-systemic-lupus-erythematosus-standard-of-care-in-2020/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exome-sequencing-for-early-pediatric-systemic-lupus-erythematosus-standard-of-care-in-2020/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology